Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

783
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
783
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

738
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
738
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

652
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
652
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

761
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
761
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

605
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
605
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

419
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
419

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

CES1 deficiency is associated with metabolic reprograming and endothelial dysfunction in pulmonary arterial hypertension.

American journal of respiratory and critical care medicine·2026
Same author

Managing a Pregnant Patient With a Mechanical Heart Valve and Subchorionic Hematomas.

JACC. Case reports·2026
Same author

Second Wave: Dynamic LVOT Obstruction in a Patient With Previous Subaortic Membrane.

Circulation. Heart failure·2026
Same author

Peripartum Cardiomyopathy: Lessons From Long-Term Outcomes in Israel.

JACC. Heart failure·2025
Same author

Right Ventricular Dysfunction and Adverse Clinical Outcomes in Peripartum Cardiomyopathy: A Meta-Analysis.

JACC. Advances·2025
Same author

What Do We Know of Human Fuel Use during Aerobic Exercise, and How Do We Know It?

Physiology (Bethesda, Md.)·2025

Video Experimental Relacionado

Updated: Mar 23, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K

Periparto Miocardiopatía

Zolt Arany1, Uri Elkayam2

  • 1From Perelman School of Medicine, University of Pennsylvania, Philadelphia (Z.A.); and Department of Medicine, Division of Cardiovascular Medicine and Department of Obstetrics and Gynecology, University of Southern California, Los Angeles (U.E.). zarany@mail.med.upenn.edu.

Circulation
|April 6, 2016
PubMed
Resumen

La cardiomiopatía periparto (PPCM) es una afección cardíaca grave durante el embarazo. Las investigaciones emergentes sugieren que los factores hormonales y genéticos contribuyen a la PPCM, lo que requiere más estudios para tratamientos efectivos.

Palabras clave:
Miocardiopatíasinsuficiencia cardíacaPre-eclampsia En el caso de laembarazo

Más Videos Relacionados

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.1K
Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

1.5K

Videos de Experimentos Relacionados

Last Updated: Mar 23, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.1K
Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

1.5K

Área de la Ciencia:

  • Cardiología
  • Obstetricia y parto
  • La genética

Sus antecedentes:

  • La cardiomiopatía periparto (PPCM) es una insuficiencia cardíaca rara pero grave asociada con el embarazo.
  • Se presenta con disfunción ventricular izquierda, a menudo en el último mes de embarazo o dentro de los cinco meses posteriores al parto.
  • Si bien la función cardíaca puede recuperarse, la morbilidad y mortalidad significativas siguen siendo motivo de preocupación.

Objetivo del estudio:

  • Revisar la epidemiología, la presentación clínica y el tratamiento de la PPCM.
  • Para resumir el conocimiento actual de la fisiopatología del PPCM.
  • Para resaltar los hallazgos recientes sobre las influencias hormonales y genéticas.

Principales métodos:

  • Revisión de la literatura de los datos epidemiológicos.
  • Análisis de las presentaciones clínicas y estrategias de manejo.
  • Síntesis de investigaciones recientes sobre la fisiopatología del PPCM.

Principales resultados:

  • La incidencia de PPCM está aumentando, aunque todavía es poco común.
  • Se utilizan tratamientos estándar de miocardiopatía, pero faltan terapias específicas para la enfermedad.
  • La disfunción vascular provocada por las hormonas y los factores genéticos están implicados en la PPCM.

Conclusiones:

  • Es crucial seguir investigando la fisiopatología del PPCM.
  • Comprender los vínculos hormonales y genéticos puede conducir a terapias dirigidas.
  • Se necesitan mejores estrategias de manejo para esta afección cardíaca asociada al embarazo.